Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Contineum Therapeutics (CTNM) Leases (2023 - 2026)

Contineum Therapeutics' Leases history spans 4 years, with the latest figure at $7.0 million for Q1 2026.

  • Quarterly Leases rose 34.02% to $7.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.0 million through Mar 2026, up 34.02% year-over-year, with the annual reading at $7.6 million for FY2025, 39.73% up from the prior year.
  • Leases came in at $7.0 million for Q1 2026, down from $7.6 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $7.6 million in Q4 2025 to a low of $231000.0 in Q2 2024.
  • The 4-year median for Leases is $5.0 million (2025), against an average of $4.1 million.
  • Year-over-year, Leases skyrocketed 2067.53% in 2025 and then surged 34.02% in 2026.
  • Contineum Therapeutics' Leases stood at $719000.0 in 2023, then surged by 660.36% to $5.5 million in 2024, then surged by 39.73% to $7.6 million in 2025, then dropped by 8.16% to $7.0 million in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Leases are $7.0 million (Q1 2026), $7.6 million (Q4 2025), and $4.8 million (Q3 2025).